Biologics and airway remodeling in severe asthma

Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling. The introduction of biologics in severe asthma has led in some patients to the complete normalization of previously considered irreversible airflow obstruction. This highlights the need to distinguish a "fixed" airflow obstruction due to structural changes unresponsive to current therapies, from a "reversible" one as demonstrated by lung function normalization during biological therapies not previously obtained even with high-dose systemic glucocorticoids. The mechanisms by which exposure to environmental factors initiates…

• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• TP
  Teva Pharmaceutical Industries
• UD
  Università degli Studi di Napoli Federico II
• RP
  Regeneron Pharmaceuticals
• RC
  Regione Campania
• C
  Cilag